Sound Medical SolutionsSound Medical Solutions allows access to the ExAblate technology gynecologists that their patients understand the need for a non-invasive, yet effective option for treatment of uterine fibroids plus . SMS was the first company to planned gynecologic access to this innovative procedure in the U.S. Now, many gynecologists are performing the ExAblate procedure and make a difference in the lives of women around the world.
Itself.According Ramirez, it is not known how the mutation in the gene associated MECP2 RS RS 1999 affected because they the disturbance of the norepinephrine. This is obviously one of the next issues that must be addressed in our experiments. .
All information, forward looking are not historical facts contained in this press looking statements-looking statements that involve risks and uncertainty, involve including Reproduction ‘ capacity raise additional capital in the a timely manner and on reasonable terms repro at all, Repros ‘ have have the capacity of success in clinical trials of the technologies that which time of application and disclosure of information in those clinical trial and the precision of such studies, a limited patient populations clinical trial up to date and the option the final dates final data might not consistent with provisional data and other risks detailed to society ‘s latest annual report be identified in form 10-K and in all downstream deliverables quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics rejects Reproduction or any intention or obligation to update or revise any forward-looking statement, whether as. Than result of new information, future events or otherwise.
On Repros Therapeutics Inc.Repros Therapeutics focused on the development of oral small molecule drugs for major unmet medical requirements to handle the male and female reproductive organs of.